@article{2998118,
    title = "Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis",
    author = "Tsivgoulis, G. and Katsanos, A.H. and Voumvourakis, K. and Hadjigeorgiou, G.M. and Heliopoulos, I. and Karapanayiotides, T. and Papathanasopoulos, P. and Kilidireas, C. and Grigoriadis, N.",
    journal = "Multiple Sclerosis and Related Disorders",
    year = "2018",
    volume = "21",
    pages = "117-119",
    publisher = "Elsevier B.V.",
    issn = "2211-0348",
    doi = "10.1016/j.msard.2018.03.010",
    keywords = "alemtuzumab;  beta1a interferon;  glatiramer;  natalizumab;  ocrelizumab;  glatiramer, clinical effectiveness;  drug efficacy;  human;  immunotherapy;  Letter;  methodology;  monotherapy;  multiple sclerosis;  randomized controlled trial (topic);  therapy effect;  treatment outcome;  multiple sclerosis, Glatiramer Acetate;  Humans;  Multiple Sclerosis;  Multiple Sclerosis, Relapsing-Remitting"
}